Related Experiment Video

Updated: May 30, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences]

F Lokiec1, J-Y Douillard

  • 1Laboratoire de pharmacologie, centre René Huguenin, institut Curie, 35, rue Dailly, 92210 Saint-Cloud, France.

Revue De Pneumologie Clinique
|July 23, 2011
PubMed

Insights

Erlotinib and gefitinib, both EGFR tyrosine kinase inhibitors (TKIs), show similar efficacy in advanced non-small cell lung cancer (NSCLC). Gefitinib demonstrated a better skin tolerance profile in one study.

Area of Science:

  • Oncology
  • Pharmacology
  • Medical Science

Background:

  • Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) are crucial in treating advanced non-small cell lung cancer (NSCLC).
  • Gefitinib is used in the first line for EGFR-mutated NSCLC, while both erlotinib and gefitinib are options for second and third-line treatments.
  • These TKIs exhibit significant activity, with response rates around 60-70% in patients with EGFR mutations.

Purpose of the Study:

  • To compare the efficacy and safety of erlotinib and gefitinib in advanced non-small cell lung cancer.
  • To evaluate their effectiveness in different lines of treatment, particularly in the context of EGFR mutations.
  • To assess the comparative tolerance profiles of these two EGFR TKIs.

Main Methods:

  • Review of pharmacological data suggesting equivalent effects of erlotinib and gefitinib.
  • Analysis of a Phase II study directly comparing erlotinib and gefitinib in second-line treatment.
  • Interpretation of indirect comparisons from Phase III trials versus chemotherapy in first-line settings.
  • Examination of cohort and Phase IV studies assessing real-world outcomes and tolerance.

Main Results:

  • Pharmacological data indicate erlotinib and gefitinib have comparable effects.
  • A Phase II study showed no significant difference in response or progression-free survival between gefitinib and erlotinib in second-line NSCLC, but gefitinib had better skin tolerance.
  • Indirect comparisons suggest equivalent response rates, though survival data require cautious interpretation due to chemotherapy arm influence.
  • Cohort and Phase IV studies confirm no significant differences in response, survival, or general tolerance profiles.

Conclusions:

  • Erlotinib and gefitinib demonstrate comparable efficacy in advanced NSCLC, particularly in EGFR-mutated cases.
  • Gefitinib may offer an advantage in terms of skin tolerance compared to erlotinib.
  • Both agents are valuable treatment options, with similar overall outcomes and tolerance profiles observed in broader studies.

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...